Related Experiment Video

Updated: Aug 18, 2026

Probiotic Studies in Neonatal Mice Using Gavage
10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

Use of probiotics in children with acute diarrhea

Hania Szajewska1, Jacek Z Mrukowicz

  • 1Department of Paediatric Gastroenterology and Nutrition, The Medical University of Warsaw, Warsaw, Poland. hania@ipgate.pl

Paediatric Drugs
|May 6, 2005
PubMed

Insights

Probiotics offer moderate, strain- and dose-dependent benefits for acute watery diarrhea in children, particularly viral gastroenteritis. Their efficacy varies by diarrhea type and early intervention is key for positive outcomes.

Area of Science:

  • Microbiology
  • Pediatrics
  • Gastroenterology

Background:

  • Probiotics, beneficial microbial preparations, are traditionally used for infection prevention.
  • Their effects on infectious diarrhea in children are moderate, strain- and dose-dependent, and influenced by diarrhea type and treatment timing.

Purpose of the Study:

  • To review the evidence on the efficacy of probiotics for preventing and treating various types of diarrhea in children.
  • To assess the strain-specificity and clinical significance of probiotic effects.

Main Methods:

  • Analysis of randomized controlled trials (RCTs) investigating probiotic use in pediatric diarrhea.
  • Evaluation of evidence for community-acquired, nosocomial, and antibacterial-associated diarrhea (AAD).

Main Results:

  • Probiotics show modest effects in preventing community-acquired diarrhea and moderate benefits for antibacterial-associated diarrhea (AAD) in children.
  • Evidence for preventing nosocomial diarrhea is conflicting, and efficacy is limited in invasive bacterial diarrhea.
  • The most documented use is for treating acute watery, presumed viral diarrhea in children.

Conclusions:

  • Probiotics are most effective for acute watery diarrhea of viral origin in children.
  • Limited evidence exists for other diarrhea types, though some preliminary results are promising.
  • Further rigorous RCTs are needed to evaluate specific probiotic strains and clinically relevant endpoints.

More Related Videos

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods08:38

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods

Published on: September 10, 2016

Related Concept Videos

Probiotics01:22

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...